Business
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
Acoramidis demonstrated a significant impact on mortality, hospitalizations, and quality of life Starting at Month 3, patients taking acoramidis showed
About this update from Bridgebio Pharma, Inc.
[{"type":"text","content":"Acoramidis demonstrated a significant impact on mortality, hospitalizations, and quality of life Starting at Month 3, patients taking acoramidis showed meaningful and sustained improvement in time to first event (CVH or ACM)Acoramidis demonstrated a 42% reduction in composite CVH and ACM events relative to placebo by Month 30Increased serum TTR levels by Day 28 were correlated with a reduced risk of events (ACM, CVM, and CVH) through Month 30Acoramidis resulted in a statistically significant reduction in ACM in the intention-to-treat (ITT) population at Month 30 Shared +2.50 cm/yr annualized height velocity (AHV) at Month 18 in Cohort 5 of PROPEL 2, the Phase 2 study of infigratinib in achondroplasia, as well as the first ever reported statistically significant improvement in body proportionalityThe first child consented in ACCEL, the observational run-in study for infigratinib in children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasiaThe Company surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)The Company ended the quarter with $587 million in cash, cash equivalents, marketable securities and short-term restricted cash PALO ALTO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases, today reported its financial results for the second quarter ended June 30, 2024, and provided an update on the Company’s operations. “Our team has continued its preparation for the commercial launch of acoramidis while also executing against our goal of fully enrolling our three Phase 3 clinical programs by the end of 2024. We are well positioned to launch acoramidis and achieve three readouts in 2025. Our differentiated capability to develop multiple candidates for genetic-based diseases provides a unique opportunity to create significant value for patients and shareholders,” said Dr. Neil Kumar, CEO and Founder of BridgeBio. Pipeline overview: ProgramStatusNext expected milestoneAcoramidis for ATTR-CMNDA filed with FDANovember 29, 2024 PDUFA dateEncaleret for ADH1Enrolling CALIBRATE, Phase 3 studyEnrollment completion in 2024BBP-418 for LGMD2I/R9Enrolling FORTIFY, ...